Kinnate Biopharma Q1 FY21: net loss $17.5M; diluted EPS −$0.40

Key figures from this report

These are the numbers Kinnate Biopharma reported for Q1 FY21, the quarter ended Mar 31, 2021, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$17.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Diluted EPS−$0.40No year-earlier figure tagged10-Q income statement, on EDGAR
3. Cash and cash equivalents$182.4MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
4. Cash from operations−$13.4MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR